CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies BLOOD
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies JNCI-J NATL CANCER I
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies MOL THER
Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma HAEMATOLOGICA
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness J IMMUNOTHER CANCER
